CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss...
Coronavirus
Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings
BATON ROUGE, La., March 23, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,...
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic...
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO,...
CancerVax Universal Cancer Vaccine Being Developed by UCLA
The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny,...
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at...
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Senior Financial Executive Judy Bjornaas Elected to DLH Board of Directors
ATLANTA, March 13, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of...
STRATA Skin Sciences Affirms No Exposure to Silicon Valley Bank
HORSHAM, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than...
UpHealth, Inc. Announces $4.5 Million Private Placement
DELRAY BEACH, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital...
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support unblinding of the data...
UpHealth Announces Strategic Sale of Innovations Group Incorporated to Belmar Pharma Solutions for Approximately $56 Million in Gross Proceeds
~ Represents a Substantial Milestone in UpHealth’s Focus on Further Integration of its Telehealth, Integrated Care and Behavioral Health Businesses...
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...